Shanghai Allist Pharmaceuticals Co. Ltd. A (688578.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100005XJ7
Shanghai Allist Pharmaceuticals Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.56 bn CNY | 5.17 bn CNY |
| Gross profit | 3.39 bn CNY | 5.17 bn CNY |
| Operating income | 1.63 bn CNY | 2.57 bn CNY |
| EBIT | 1.62 bn CNY | 2.53 bn CNY |
| Net income | 1.43 bn CNY | 2.18 bn CNY |
| Diluted EPS – continuing operations | 3.18 CNY | 4.85 CNY |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
More stocks
- Installed Building Products, Inc. (IBP)
- HD Hyundai Marine Solution (443060.KS)
- LG CNS (064400.KS)
- ALLEGRO MICROSYSTEMS, INC. (ALGM)
- Perseus Mining Ltd (PRU.AX)
- Broadex Technologies Co Ltd (300548.SZ)
- Anhui Yingjia Distillery Co Ltd (603198.SS)
- OUTFRONT Media Inc. (OUT)
- EAGLE MATERIALS INC (EXP)
- Yancoal Australia Ltd (YAL.AX)
- Georg Fischer AG (GF.SW)
- ASSOCIATED BANC-CORP (ASB)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.